Group Leader, Regenerative Medicine Program of IDIBELL
Group Leader of P-CMRC
Dr Jordi Guiu studied BS in Biology (2006), Biochemistry (2007) and a Master of Science in Molecular Biotechnology (2008). Then he did a PhD in Biomedicine (2012) from Pompeu Fabra University to study the genetic circuitry that controls the establishment of hematopoietic stem cells. Subsequently he joined Dr. Kim B. Jensen lab (Copenhagen University) as a postdoc, were he obtained a Marie Curie fellowship (2014-2019). His postdoctoral work focused on the specification of intestinal stem cells during development using fate mapping technologies, state of the art imaging, biophysical modeling and a plethora of sequencing techniques. In 2019 Dr. Guiu was appointed Assistant Professor in Copenhagen University. In September 2019, he joined the P-CMRC/IDIBELL as independent group leader.
Dr Guiu pursue a research program aimed at improving quality of life for cancer survivors, which suffer side effects of radiotherapy including acute and chronic inflammation of the intestine known as radiation-induced enteritis.
Mònica Díaz Ferrer
Mònica Díaz holds a bachelor degree in Biochemistry and a PhD in Physiology from the University of Barcelona. During the PhD she studied the role of insulin regulating the glucose transport in skeletal muscle under the supervision of Dr Josep Planas. After finishing her PhD she stayed at the same laboratory as a postdoctoral researcher and assistant professor for one year.
In 2008, she did a short stay as postdoctoral researcher in CIBBIM-Nanomedicine at the Vall d’Hebron Research Institute, in the laboratory of Dr Julián Cerón that was focused on the modeling of human diseases in C. elegans.
Then she moved to Omnia Molecular, a biotech company devoted to the design and development of new anti-infectives targeted at difficult-to-treat infections, as a project manager. She was involved in the setup and development of a proprietary technology platform. Among her tasks, she was in charge of the cell-based assays, in particular their design and miniaturization to be incorporated into a high-throughput screening campaign.
In 2013, she joined the CMR[B] as a research assistant. Here, she has been involved in several projects aimed to model in vitro different diseases through the generation of patient-derived pluripotent stem cells.
Since September 2020, she works as a research assistant in the Cell plasticity and Regeneration group at P-CMR[C].